1. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A,non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 1986;315(25):1575-1578.

2. Di Bisceglie AM, Martin P, Kassianides C, et al. Recombinant interferon alfa therapy for chronic hepatitis C. A randomized, double-blind, placebo-controlled trial. N Engl J Med. 1989;321(22):1506-1510.

3. Davis GL, Balart LA, Schiff ER, et al. Treatment of chronic hepatitis C with recombinant alfa-interferon. A multicenter randomized, controlled trial. The Hepatitis Interventional Therapy Group. J Hepatol. 1990;11(Suppl 1):S31-35.

4. Causse X, Godinot H, Chevallier M, et al. Comparison of 1 or 3 MU of interferon alfa-2b and placebo in patients with chronic non-A, non-B hepatitis. Gastroenterology. 1991;101(2):497-502.

5. Marcellin P, Boyer N, Giostra E, et al. Recombinant human alpha-interferon in patients with chronic non-A, non-B hepatitis: a multicenter randomized controlled trial from France. Hepatology. 1991;13(3):393-397.

6. Lee WM. Therapy of hepatitis C: interferon alfa-2a trials. Hepatology. 1997;26(3 Suppl 1):89-95S.

7. Chemello L, Bonetti P, Cavalletto L, et al. Randomized trial comparing three different regimens of alpha-2a- interferon in chronic hepatitis C. The TriVeneto Viral Hepatitis Group. Hepatology. 1995;22(3):700-706.

8. Rumi M, Del Ninno E, Parravicini ML, et al. A prospective, randomized trial comparing lymphoblastoid to recombinant interferon alfa 2a as therapy for chronic hepatitis C. Hepatology. 1996;24(6):1366-1370.

9. Diodati G, Bonetti P, Noventa F, et al. Treatment of chronic hepatitis C with recombinant human interferon- alpha 2a: results of a randomized controlled clinical trial. Hepatology. 1994;19(1):1-5.

10. Douglas DD, Rakela J, Lin HJ, et al. Randomized controlled trial of recombinant alpha-2a-interferon for chronic hepatitis C. Comparison of alanine aminotransferase normalization versus loss of HCV RNA and anti-HCV IgM. Dig Dis Sci. 1993;38(4):601-607.

11. Keeffe EB, Hollinger FB. Therapy of hepatitis C: consensus interferon trials. Consensus Interferon Study Group. Hepatology. 1997;26(3 Suppl 1):101-107S.

12. Tong MJ, Reddy KR, Lee WM, et al. Treatment of chronic hepatitis C with consensus interferon: a multicenter, randomized, controlled trial. Consensus Interferon Study Group. Hepatology. 1997;26(3):747-754.

13. Poynard T, Leroy V, Cohard M, et al. Meta-analysis of interferon randomized trials in the treatment of viral hepatitis C: effects of dose and duration. Hepatology. 1996;24(4):778-789.

14. Lin R, Roach E, Zimmerman M, et al. Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. Results of the first multicentre Australian trial. Australia Hepatitis C Study Group. J Hepatol. 1995;23(5):487-496.

15. Manesis EK, Papaioannou C, Gioustozi A, et al. Biochemical and virological outcome of patients with chronic hepatitis C treated with interferon alfa-2b for 6 or 12 months: a 4-year follow- up of 211 patients. Hepatology. 1997;26(3):734-739.

16. Poynard T, Bedossa P, Chevallier M, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. Multicenter Study Group. N Engl J Med. 1995;332(22):1457-1462.

17. Reichard O, Foberg U, Fryden A, et al. High sustained response rate and clearance of viremia in chronic hepatitis C after treatment with interferon-alpha 2b for 60 weeks. Hepatology. 1994;19(2):280-285.

18. Carithers RL, Jr, Emerson SS. Therapy of hepatitis C: meta-analysis of interferon alfa-2b trials. Hepatology. 1997;26(3 Suppl 1):83-88S.

19. EASL: International Consensus Conference on Hepatitis C Consensus Statement. J Hepatol. 1999;30(5):956-961.

20. Schalm SW, Weiland O, Hansen BE, et al. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis. Gastroenterology. 1999;117(2):408-413.

21. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR. 1998;47(No. RR-19):1-39.

22. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet. 1998;352(9138):1426-1432.

23. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med. 1998;339(21):1485-1492.

24. Poynard T, McHutchison J, Goodman Z, et al. Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group. Hepatology. 2000;31(1):211-218.

25. Schalm SW, Hansen BE, Chemello L, et al. Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers. J Hepatol. 1997;26(5):961-966.

26. Reddy KR. Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs. Ann Pharmacother. 2000;34(7-8):915-923.

27. Kozlowski A, Harris JM. Improvements in protein PEGylation: pegylated interferons for treatment of hepatitis C. J Control Release. 2001;72(1-3):217-224.

28. Zeuzem S, Feinman SV, Rasenack J, et al. Peginterferon alfa-2a in patients with chronic hepatitis C. N Engl J Med. 2000;343(23):1666-1672.

29. Heathcote EJ, Shiffman ML, Cooksley W, et al. Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. N Engl J Med. 2000;343(23):1673-1680.

30. Glue P, Rouzier-Panis R, Raffanel C, et al. A dose-ranging study of pegylated interferon alfa-2b and ribavirin in chronic hepatitis C. The Hepatitis C Intervention Therapy Group. Hepatology. 2000;32(3):647-653.

31. Fried M, Shiffman M, Reddy R, et al. Pegylated (40 kDa) interferon alfa-2a (PEGASYS) in combination with ribavirin: efficacy and safety results from a phase III, randomized, actively-controlled, multicenter study. Gastroenterology. 120 (Suppl), A55. 2001. (Abstract).

32. Manns M, McHutchison J, Gordon S, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatmentof chronic hepatitis C: a randomized trial. Lancet. 2001;358(9286):958-965.

33. Trepo C, Lindsey K, Niederau C, et al. Pegylated interferon alfa-2b (PEG-INTRON) monotherapy is superior to interferon alfa-2b (INTRON A) for the treatment of chronic hepatitis C. J Hepatol. 2000;32(S2):29.

34. Sulkowski M, Reindollar R, Yu J. Pegylated interferon alfa-2a (PEGASYS) and ribavirin combination therapy for chronic hepatitis C: a phase II open-label study. Gastroenterology. 188(S2), A950. 2000. (Abstract).

35. Jacobson IM, Russo M, Brown R, et al. Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: a trial in prior nonresponders to interferon monotherapy or combination therapy, and in combination therapy relapsers. Gastroenterology. 120(S1). 2001. (Abstract).

36. Craxi A, Licata A. Clinical trial results of peginterferons in combination with ribavirin. Semin Liver Dis. 2003;23 Suppl 1:35-46.

37. Zeuzem S, Welsch C, Herrmann E. Pharmacokinetics of peginterferons. Semin Liver Dis. 2003;23 Suppl 1:23-8.

38. Pedder SC. Pegylation of interferon alfa: structural and pharmacokinetic properties. Semin Liver Dis. 2003;23 Suppl 1:19-22.

39. Powers KA, Dixit NM, Ribeiro RM, Golia P, Talal AH, Perelson AS. Modeling viral and drug kinetics: hepatitis C virus treatment with pegylated interferon alfa-2b. Semin Liver Dis. 2003;23 Suppl 1:13-8.

40. Sherman KE. Implications of peginterferon use in special populations infected with HCV. Semin Liver Dis. 2003;23 Suppl 1:47-52.

41. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347(13):975-982.

42. Hadziyannis SJ, Sette H Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med. 2004;140(5):346-55.

43. Reddy KR, Wright TL, Pockros PJ, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology. 2001;33(2):433-438.

44. Hassanein T, et.al. Treatment with 40kda peginterferon alfa-2a (Pegasys) in combination with ribavirin significantly enhances quality of life compared with interferon alpha-2b plus ribavirin. Hepatology. 2001;34:243A (abstract). [Note: This abstract is not available on the National Library of Medicine database PubMed.]

45. Perrillo RP, Rothstein K, Alam I, et al. Efficacy, safety, and tolerability in patients switched to PEG (40 kDa) IFN alfa-2a (PEGASYS) after discontinuation from interferon alfa-2b plus ribavirin (REBETRON) combination therapy for chronic hepatitis C. Gastroenterology. 120(S1), A567. 2001. (Abstract).

46. Rothstein K, Perrillo RP, Imperial J, et al. Efficacy, quality of life, safety, and tolerability in patients with chronic hepatitis C treated with PEG (40 kDa) IFN alfa-2a (PEGASYS) or standard interferon alfa-2b/ribavirin (REBETRON) combination therapy. Gastroenterology. 120(S1), A77. 2001. (Abstract).

47. Bernstein D, Cooksley G, Fried MW, et al. Correlation of health-related quality of life with virological response and early treatment discontinuation in patients treated with pegylated (40 kDa) interferon alfa-2a (PEGASYS) compared with standard interferon alfa-2a. Gastroenterology. 120(S1), A382. 2001. (Abstract).

48. National Institutes of Health Consensus Development Conference: Management of Hepatitis C: 2002. Hepatology. 2002;36(5):Suppl 1. [At the time of publication, the final consensus statement was available at: http://consensus.nih.gov/cons/116/Hepc091202.pdf

49.Sjogren M, Holtzmuller K, Smith M, Sjogren, Jr R. Sustained antiviral response with consensus interferon (CIFN) plus ribavirin or interferon alfa-2b (IFN alfa-2b) plus ribavirin in treatment-naïve subjects with chronic hepatitis C. A pilot study. Hepatology. 2002;36:311A (abstract). [Note: This abstract is not available on the National Library of Medicine database PubMed.]

50. Kaiser S, Hass H, Gregor M. High dose induction therapy with consensus interferon and ribavirin for treatment-naïve patients with hepatitis C. Hepatology. 2002:36:362A (abstract). [Note: This abstract is not available on the National Library of Medicine database PubMed.]

51. Kaiser S, Hass H, Gregor M. High viral response rates in previous interferon/ribavirin nonresponder patients with chronic hepatitis C retreated with consensus interferon induction therapy and ribavirin. Hepatology. 2002;36:358A (abstract). [Note: This abstract is not available on the National Library of Medicine database PubMed.]

52. Jaeckel E, Cornberg M, Wedemeyer H, et al. Treatment of acute hepatitis C with interferon alfa-2b. N Engl J Med. 2001;345(20):1452-7.

53. Marcellin P, Levy S, Erlinger S. Therapy of hepatitis C: patients with normal aminotransferase levels. Hepatology. 1997;26(3 Suppl 1):133-136S.

54. Zeuzem S. Treatment of chronic hepatitis C virus infection in patients with cirrhosis. J Viral Hepat. 2000;7(5):327-334.

55. Gumber SC, Chopra S. Hepatitis C: a multifaceted disease. Review of extrahepatic manifestations. Ann Intern Med. 1995;123(8):615-620.

56. Cacoub P, Poynard T, Ghillani P, et al. Extrahepatic manifestations of chronic hepatitis C. MULTIVIRC Group. Multidepartment Virus C. Arthritis Rheum. 1999;42(10):2204-2212.

57. Darby SC, Ewart DW, Giangrande PL, et al. Mortality from liver cancer and liver disease in haemophilic men and boys in UK given blood products contaminated with hepatitis C. UK Haemophilia Centre Directors' Organisation. Lancet. 1997;350(9089):1425-1431.

58. Benhamou Y, Bochet M, Di Martino V, et al. Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology. 1999;30(4):1054-1058.

59. Daar ES, Lynn H, Donfield S, et al. Relation between HIV-1 and hepatitis C viral load in patients with hemophilia. J Acquir Immune Defic Syndr. 2001;26(5):466-472.

60. Cinelli R, Di Gennaro G, Nasti G, et al. Efficacy and safety of combined treatment with pegylated-IFN-alpha 2b plus ribavirin in HIV-hepatitis C virus-co-infected patients. AIDS. 2004;18(7):1079-80.

61. Perez-Olmeda M, Nunez M, Romero M, et al. Pegylated IFN-alpha2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS. 2003;17(7):1023-8.

62. Chung RT, Andersen J, Volberding P, et al. Peginterferon Alfa-2a plus ribavirin versus interferon alfa-2a plus ribavirin for chronic hepatitis C in HIV-coinfected persons. N Engl J Med. 2004;351(5):451-9.

63. Torriani FJ, Rodriguez-Torres M, Rockstroh JK, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med. 2004;351(5):438-50.

64. Lau DT, Kleiner DE, Ghany MG, Park Y, Schmid P, Hoofnagle JH. 10 year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology. 1998 Oct;28(4):1121-1127.

65. Nishiguchi S, Kuroki T, Nakatani S, et al. Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet. 1995;346(8982):1051-1055.

66. Fattovich G, Giustina G, Degos F, et al. Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). J Hepatol. 1997;27(1):201-205.

67. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112(2):463-472.

68. Mazzella G, Accogli E, Sottili S, et al. Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. J Hepatol. 1996;24(2):141-147.

69. C, Giunta M, Andreone P, Craxi A. Interferon and prevention of hepatocellular carcinoma in viral cirrhosis: an evidence-based approach. J Hepatol. 2001;34(4):593-602.

70. Baffis V, Shrier I, Sherker AH, Szilagyi A. Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection. Ann Intern Med. 1999;131(9):696-701.

71. Ikeda K, Saitoh S, Kobayashi M, et al. Long-term interferon therapy for 1 year or longer reduces the hepatocellular carcinogenesis rate in patients with liver cirrhosis caused by hepatitis C virus: a pilot study. J Gastroenterol Hepatol. 2001;16(4):406-415.

72. Afdhal NH, Dieterich DT, Pockros PJ, et al. Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology. 2004;126(5):1302-11.

73. Dieterich DT, Wasserman R, Brau N, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol. 2003;98(11):2491-9.

74. Soza A, Everhart JE, Ghany MG, et al. Neutropenia during combination therapy of interferon alfa and ribavirin for chronic hepatitis C. Hepatology. 2002;36(5):1273-9.

75. Van Thiel DH, Faruki H, Friedlander L, et al. Combination treatment of advanced HCV associated liver disease with interferon and G-CSF. Hepatogastroenterology. 1995;42(6):907-12.

76. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123(4):1061-9.

77. Davis GL, Wong JB, McHutchison JG, Manns MP, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology. 2003;38(3):645-52.

78. Shiffman ML, Di Bisceglie AM, Lindsay KL, et al. Peginterferon alfa-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology. 2004;126(4):1015-23; discussion 947.